ESR1 and neoplasm: The reason for this is unclear, but may be due to an increased propensity for bleeding brought about by an interaction between vitamin K antagonists and selective estrogen receptor modulators used to inhibit tumor growth19or generally more intense antitumoral treatment which we could not adjust for.